All In Biotech

Drug Trial Radar · NCT02558374

Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension

A Double-masked, Randomized, Multi-center, Active-controlled, Parallel Group, 6-month Study With a 3-month Interim Analysis Assessing the Ocular Hypotensive Efficacy and Safety of AR-13324 Ophthalmic Solution, 0.02% QD Compared to Timolol Maleate Ophthalmic Solution, 0.5% BID in Patients With Elevated Intraocular Pressure

Last checked: Nov 19, 2026Latest source record: Apr 6, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 708 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

708

Actual

Start

Sep 2015

Primary completion

Dec 2016

Study completion Dec 2016

Sponsor

Lead sponsor
Aerie PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Sep 24, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate ocular hypotensive efficacy and safety of Netarsudil (AR-13324) Ophthalmic Solution compared to Timolol Maleate Ophthalmic Solution.

Conditions

  • Open-angle Glaucoma
  • Ocular Hypertension

Interventions

  • AR-13324 Ophthalmic Solution 0.02%Drug

    1 drop once daily (QD), PM, OU

  • Timolol Maleate Ophthalmic Solution 0.5% BIDDrug

    1 drop BID, AM/PM, OU

  • PlaceboOther

    1 drop QD, AM, OU

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. IOP (Intraocular Pressure)Time frame: 3 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Aerie Pharmaceuticals

    Bedminster, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.